Lumigan Ophthalmic Solution (Bimatoprost Eye Drops)

Lumigan Ophthalmic Solution (Bimatoprost Eye Drops)
© The Swiss Pharmacy

Lumigan Ophthalmic Solution (Bimatoprost Eye
Drops) is a prostaglandin analog indicated for the
reduction of elevated intraocular pressure in patients
with open angle glaucoma or ocular hypertension.
Lowering high pressure inside the eye can help
prevent blindness.
This medication works by regulating the flow of fluid
within the eye to maintain a normal pressure.

Lumigan Ophthalmic Solution
is manufactured by Allergan
Inc. (Manufactured in the USA)
in the strengths of 0.03 % and
0.01 %.

Chemical Structure

The active ingredient contained in
Lumigan Ophthalmic Solution is
Bimatoprost.
Each ml of Lumigan Ophthalmic Solution
contains 0.1 mg or 0.3 mg of
Bimatoprost.

Uses of Lumigan 0.01 % and 0.03 % Ophthalmic Solution:
Lumigan Ophthalmic Solution (Bimatoprost Eye Drops) is used for the
reduction of elevated intraocular pressure in patients with open angle
glaucoma or ocular hypertension. This medicine may be used on its own or
with other drops called beta-blockers which also reduce pressure.
Your eye contains a clear, watery liquid that feeds the inside of the eye. Liquid
is constantly being drained out of the eye and new liquid is made to replace
this. If the liquid cannot drain out quickly enough, the pressure inside the eye
builds up.
This medicine works by increasing the amount of liquid that is drained. This
reduces the pressure inside the eye. If the high pressure is not reduced, it could
lead to a disease called glaucoma and eventually damage your sight.
Lumigan may also be used to increase the size of the eyelashes.

Recommended Adult Dosage
The dose of
Lumigan (Bimatoprost Ophthalmic Solution) is one
drop in the affected eye(s) once daily in the evening.
Use in pediatric patients below the age of 16 years is
not recommended because of potential safety
concerns related to increased pigmentation
following long-term chronic use.

Contraindications
➔Lumigan Ophthalmic Solution is contraindicated
in patients with a known hypersensitivity to
Bimatoprost or any component of the solution.

Storage Instructions
Lumigan Ophthalmic Solution (Bimatoprost
Eye Drops) have to be stored at controlled
room temperature i.e. from 20°C to 25°C
(68°F to 77°F) with excursions permitted
between 15° to 30°C (59° to 86°F).
Keep this as well as all other medicines
away from children and pets.

Warnings
Lumigan eye drops (Bimatoprost ophthalmic solution) has been reported to
cause changes to pigmented tissues. The most frequently reported changes
have been increased pigmentation of the iris, periorbital tissue (eyelid) and
eyelashes. Pigmentation is expected to increase as long as Bimatoprost is
administered.
Lumigan 0.01% and 0.03% ophthalmic solution may gradually change
eyelashes and vellus hair in the treated eye. These changes include increased
length, thickness, and number of lashes. Eyelash changes are usually reversible
upon discontinuation of treatment.
Macular edema, including cystoid macular edema, has been reported during
treatment with Bimatoprost ophthalmic solution. Lumigan 0.01% and 0.03%
should be used with caution in aphakic patients, in pseudophakic patients with
a torn posterior lens capsule, or in patients with known risk factors for macular
edema.

Warnings
Lumigan 0.01% and 0.03% has not been evaluated for the treatment of
angle-closure, inflammatory or neovascular glaucoma.
There have been reports of bacterial keratitis associated with the use of
multiple-dose containers of topical ophthalmic products. These
containers had been inadvertently contaminated by patients who in most
cases had a concurrent corneal disease or a disruption of the ocular
epithelial surface.
Bimatoprost ophthalmic solution contains Benzalkonium Chloride, which
may be absorbed by and cause discoloration of soft contact lenses.
Contact lenses should be removed prior to application of Lumigan eye
drops and may be reinserted 15 minutes following its administration.

Warnings
There is the potential for hair growth to occur in areas where Bimatoprost
ophthalmic solution comes in repeated contact with the skin surface. It is important
to apply Bimatoprost ophthalmic solution only to the skin of the upper eyelid margin
at the base of the eyelashes using the accompanying sterile applicators, and to
carefully blot any excess Lumigan eye drops from the eyelid margin to avoid it
running onto the cheek or other skin areas.
Bimatoprost ophthalmic solution should be used with caution in patients with active
intraocular inflammation (e.g., uveitis) because the inflammation may be
exacerbated.
The Lumigan ophthalmic solution bottle must be kept intact during use. It is
important to use bimatoprost ophthalmic solution as instructed, by placing one drop
on the single-use-per eye applicator. The bottle tip should not be allowed to contact
any other surface since it could become contaminated. The accompanying sterile
applicators should only be used on one eye and then discarded since reuse of
applicators increases the potential for contamination and infections.

Driving And Using Machines
Your sight may become blurred for a short time just
after using Lumigan ophthalmic solution. You should
not drive or use machines until your sight is clear
again.

Possible Side Effects
The most frequently reported side effects during clinical trials were eye
pruritus, conjunctival hyperemia, skin hyperpigmentation, ocular
irritation, dry eye symptoms, and periorbital erythema. These reactions
occurred in less than 4% of patients. Additional side effects seen in clinical
trials experience include foreign body sensation, hair growth abnormal,
and iris hyperpigmentation.
Additional side effects reported with Bimatoprost ophthalmic solution
(Lumigan eye drops) for the reduction of intraocular pressure include,
ocular dryness, visual disturbance, ocular burning, eye pain, blepharitis,
cataract, superficial punctate keratitis, eye discharge, tearing,
photophobia, allergic conjunctivitis, asthenopia, conjunctival edema, iritis,
infections (primarily colds and upper respiratory tract infections),
headaches, and asthenia.

Lumigan Eye Drops Overdosage
No information is available on overdosage in humans. If
overdose with Lumigan Eye Drops 0.01% and 0.03%
(Bimatoprost Ophthalmic Solution) occurs, treatment should
be symptomatic.
In short-term oral (by gavage) mouse and rat studies, doses
up to 100 mg/kg/day did not produce any toxicity.

Lumigan Ophthalmic Solution During Pregnancy
Bimatoprost (Lumigan Ophthalmic Solution) has been classified by the
US FDA as Pregnancy Category C.
During embryo/fetal developmental studies in pregnant mice and rats,
abortion was observed at oral doses of Bimatoprost which achieved at
least 33 or 97 times, respectively, the maximum intended human
exposure based on blood AUC levels.
There are no adequate and well-controlled studies of Lumigan 0.01%
and 0.03% Eye Drops (Bimatoprost Ophthalmic Solution) administration
in pregnant women. Because animal reproductive studies are not always
predictive of human response Lumigan Ophthalmic Solution should be
administered during pregnancy only if the potential benefit justifies the
potential risk to the fetus.

Lumigan Ophthalmic Solution is manufactured by
Allergan Inc. (Manufactured in the USA).
For More details Click Here

Lumigan Ophthalmic Solution (Bimatoprost Eye Drops)

Recommended

Recommended

More Related Content

What's hot

What's hot (20)

Similar to Lumigan Ophthalmic Solution (Bimatoprost Eye Drops)

Similar to Lumigan Ophthalmic Solution (Bimatoprost Eye Drops) (20)

More from The Swiss Pharmacy

More from The Swiss Pharmacy (20)

Recently uploaded

Recently uploaded (20)

Lumigan Ophthalmic Solution (Bimatoprost Eye Drops)